ClinicalTrials.gg
CompletedNCT00980174Updated Oct 17, 2018Results posted

Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis

A Phase 3 interventional study of 60 mg denosumab and Placebo in Low Bone Mass, Low Bone Mineral Density and Males With Osteoporosis, sponsored by Amgen. Completed. Open to male participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-10-17.

Primary conditionOsteoporosisRegistry: Bone Diseases, MetabolicReclassifiedWhy we changed it
Registry
Bone Diseases, Metabolic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Osteoporosis
Why
  1. The study's listed conditions name Osteoporosis, a narrower term within Bone Diseases, Metabolic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
242
Allocation
Randomized
Ages
30 Years to 85 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies testing denosumab in Osteoporosis — 8 open to participants now, 11 under way, 2 of them phase 3. Denosumab · Osteoporosis.

Enrollment
18th of 64
242 · median 90
Started
2009
with 4 others
Phase 3
24 of 64
2 open now
Registered
17th of 64
by date
Lead sponsor
22 of 64
Amgen

Among the 64 studies testing denosumab in Osteoporosis, this one is the 18th largest by enrollment, is one of 5 that started in 2009, is one of 24 in phase 3, and was the 17th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

8 of the 64 studies testing denosumab in Osteoporosis are open now, in 8 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 30 Years to 85 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing denosumab in Osteoporosis, or all of them as a file.
02

Study summary

The purpose of this study is to assess how effective and safe denosumab is in a population of males with low bone mass at risk of fracture. The primary clinical hypothesis is that in men with low bone mineral density, the mean percent change in lumbar spine bone mineral density at 12 months in subjects receiving denosumab will be greater than in subjects receiving placebo. Denosumab is a fully human monoclonal antibody with a high affinity for Receptor Activator of Nuclear Factor (RANK) Ligand that can bind and neutralize the activity of human RANK Ligand similar to the action of endogenous osteoprotegerin.

03

Conditions studied

  • Low Bone Mass
  • Low Bone Mineral Density
  • Males With Osteoporosis
  • Osteopenia
  • Osteoporosis

Browse trials for

Keywords

  • men
  • male
  • denosumab
  • BMD
  • lumbar spine
  • ADAMO
  • The ADAMO Trial
  • male osteoporosis
  • osteoporosis in men
  • males with low bone mineral density
04

In context

Osteoporosis Reclassified

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

This study's enrollment of 242 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.

Browse Osteoporosis studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Osteoporosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Bone Diseases, Metabolic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
30 Years to 85 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Bone Mineral Density (BMD) values (g/cm2) assessed by the local site at either the lumbar spine OR femoral neck that occur within the ranges specified in the protocol OR For subjects with a history of a major osteoporotic fracture (clinical vertebral, hip, humerus and distal radius fractures) occurring more than 6 months prior to screening, BMD values (g/cm2) assessed by the local site, at either the lumbar spine OR femoral neck that occur within the ranges specified in the protocol.
  • At least 2 lumbar vertebrae, at least 1 hip and at least one forearm must be evaluable by Dual X ray Absorptiometry (DXA).
  • Ambulatory males 30 to 85 years of age inclusive at the start of screening.
  • Provide the appropriate written before any study specific procedure.

Exclusion criteria

Exclusion Criteria:

  • BMD values (g/cm2) as specified in the protocol in subjects with or without a history of major osteoporotic fractures, based on the particular scanner that is used.
  • Any disorder that compromises the ability of the subject to give written and/or to comply with study procedures.
  • Any severe or more than 1 moderate vertebral fractures on screening spinal x ray
  • Any vertebral fracture diagnosed within the 6 months prior to screening
  • Any clinical fracture within the last 6 months prior to screening
  • For males with a partner of : Subject refuses to use 2 highly effective methods of for the duration of the study and for 10 months after the last dose of study medication.
  • For males with a partner who is pregnant: Subject refuses to use a condom for the duration of the study and for 10 months after the last dose of study medication.
  • Previous participation in clinical trials with denosumab or administration of commercial denosumab.
  • Currently enrolled in or has not yet completed at least 1 month since ending other device or drug trial(s), or subject is receiving other investigational agent(s).
  • Vitamin D deficiency [25(OH) vitamin D level \< 20 ng/mL (\< 49.9 nmol/L)]. Vitamin D replenishment will be permitted and subjects may be re-screened; see Section 7.
  • Hyper- or hypothyroidism; however, stable subjects, in the investigator's opinion, on thyroid hormone replacement therapy are allowed.
  • Hyper- or hypoparathyroidism. Intact parathyroid hormone (iPTH) values outside of the reference range as determined by the central laboratory
  • Elevated transaminases. Serum ; serum glutamate-oxaloacetic transaminase > 2.5 x . Serum alanine aminotransferase; serum glutamate pyruvate transaminase > 2.5 x upper limit of normal (both as determined by the central laboratory).
  • Significantly impaired renal function as determined by a derived (using the Modification of Diet in Renal Disease formula) of less than or equal to 30 mL/min/1.73 m2 calculated by the central laboratory.
  • Hypo- or hypercalcemia based on the central laboratory reference ranges for albumin-adjusted serum calcium.
  • Known to have tested positive for , virus, surface antigen or cirrhosis of the liver.
  • (except fully resected cutaneous basal cell or squamous cell carcinoma) within the last 5 years.
  • Any metabolic bone disease, eg osteomalacia, osteogenesis imperfecta, rheumatoid arthritis, Paget's disease, Cushing's disease or, hyperprolactinemia which may interfere with the interpretation of the findings OR evidence of malabsorption syndromes which might interfere with absorption of vitamin D.
  • Received any solid organ or bone marrow transplant or is on chronic for any reason.
  • Any laboratory abnormality, which in the opinion of the investigator or Amgen, will prevent the subject from completing the study or interfere with the interpretation of the study results.
  • Administration of intravenous bisphosphonate, or fluoride (except for dental treatment) or strontium ranelate.
  • Oral bisphosphonate treatment:
  • greater than or equal to 3 months cumulatively in the past 2 years, OR
  • greater than or equal to 1 month in the past year, OR
  • Any use during the 3-month period prior to randomization
  • Administration of any of the following treatments 3 months prior to screening:
  • Anabolic steroids or testosterone
  • Glucocorticosteroids (greater than or equal to 5 mg prednisone equivalent per day for more than 10 days or a total cumulative dose of greater than or equal to 50 mg)
  • Calcitonin
  • Calcitriol or vitamin D derivatives [vitamin D contained in supplements or multivitamins is allowed]
  • Other bone active drugs including anti-convulsives (except benzodiazepines) and heparin
  • Chronic systemic ketoconazole, adrenocorticotrophic hormone (ACTH), cinacalcet, aluminum, lithium, protease inhibitors, methotrexate, gonadotropin-releasing hormone agonists.
  • Androgen deprivation therapy
  • Known sensitivity to mammalian cell derived drug products.
  • Known intolerance to calcium or vitamin D supplements.
  • Height, weight or girth which may preclude accurate DXA measurements.
  • Bilateral hip replacements
  • Any physical or psychiatric disorder which, in the opinion of the investigator or Amgen, will prevent the subject from completing the study or interfere with the interpretation of the study results.
  • Evidence of alcohol or substance-abuse within the last 12 months which the investigator believes would interfere with understanding of or completion of the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
242 participants (actual)

Study arms

  • Placebo comparator
    2

    Subjects will receive placebo for denosumab (SC injection every 6 months) for 1 year (double-blind phase) followed by 60 mg denosumab (SC injection every 6 months) for 1 year (open-label phase)

    Drug: 60 mg denosumab · Other: Placebo

  • Experimental
    1

    60 mg denosumab (SC injection every 6 months) for 1 year (double-blind phase) followed by 60 mg denosumab(SC injection every 6 months) for 1 year (open-label phase). These subjects will be on denosumab for a total of 2 years.

    Drug: 60 mg denosumab

Interventions

  • 60 mg denosumab (SC injection every 6 months)

    Also known as: denosumab

  • OtherPlacebo

    Placebo for denosumab (SC injection every 6 months)

07

What researchers measure

Primary outcomes

  1. Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12

    Time frame: From Baseline to 12 Months

Secondary outcomes

  1. Total Hip Bone Mineral Density Percent Change From Baseline at Month 12

    Time frame: From Baseline to 12 Months

  2. Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12

    Time frame: From Baseline to 12 Months

  3. Trochanter Bone Mineral Density Percent Change From Baseline at Month 12

    Time frame: From Baseline to 12 Months

  4. Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12

    Time frame: From Baseline to 12 Months

  5. Serum Type 1 Collagen C-telopeptide (CTX) Percent Change From Baseline at Day 15

    Time frame: From Baseline to Day 15

08

Results

Posted Nov 29, 2012

Participant flow

Participant flow — Overall Study
MilestonePlaceboDenosumab 60 mg Q6M
Started121121
Completed117111
Not completed410
Withdrew: Withdrawal by subject14
Withdrew: Adverse event03
Withdrew: Ineligibility determined21
Withdrew: Death11
Withdrew: Other01

Outcome measures

PrimaryLumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12
Time frame:
From Baseline to 12 Months
Reported as:
Mean · Percent
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12
PercentPlaceboDenosumab 60 mg Q6M
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 120.9 (0.3 to 1.4)5.7 (5.1 to 6.2)
Statistical analysis
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = <0.0001 · Mean difference (net): 4.8 · 95% CI 4.0 to 5.6Denosumab - Placebo
SecondaryTotal Hip Bone Mineral Density Percent Change From Baseline at Month 12
Time frame:
From Baseline to 12 Months
Reported as:
Mean · Percent
Total Hip Bone Mineral Density Percent Change From Baseline at Month 12
PercentPlaceboDenosumab 60 mg Q6M
Total Hip Bone Mineral Density Percent Change From Baseline at Month 120.3 (-0.1 to 0.7)2.4 (2.0 to 2.7)
Statistical analysis
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = <0.0001 (p-value is adjusted for multiple comparisons by Hochberg method) · Mean difference (net): 2.0 · 95% CI 1.5 to 2.6Denosumab - Placebo
SecondaryFemoral Neck Bone Mineral Density Percent Change From Baseline at Month 12
Time frame:
From Baseline to 12 Months
Reported as:
Mean · Percent
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12
PercentPlaceboDenosumab 60 mg Q6M
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 120.0 (-0.6 to 0.6)2.1 (1.5 to 2.8)
Statistical analysis
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = <0.0001 (p-value is adjusted for multiple comparisons by Hochberg method) · Mean difference (net): 2.2 · 95% CI 1.3 to 3.0Denosumab - Placebo
SecondaryTrochanter Bone Mineral Density Percent Change From Baseline at Month 12
Time frame:
From Baseline to 12 Months
Reported as:
Mean · Percent
Trochanter Bone Mineral Density Percent Change From Baseline at Month 12
PercentPlaceboDenosumab 60 mg Q6M
Trochanter Bone Mineral Density Percent Change From Baseline at Month 120.8 (0.2 to 1.4)3.1 (2.5 to 3.7)
Statistical analysis
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = <0.0001 (p-value is adjusted for multiple comparisons by Hochberg method) · Mean difference (net): 2.3 · 95% CI 1.4 to 3.2Denosumab - Placebo
SecondaryDistal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12
Time frame:
From Baseline to 12 Months
Reported as:
Mean · Percent
Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12
PercentPlaceboDenosumab 60 mg Q6M
Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12-0.3 (-0.8 to 0.2)0.6 (0.1 to 1.1)
Statistical analysis
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = 0.0144 (p-value is adjusted for multiple comparisons by Hochberg method) · Median difference (net): 0.9 · 95% CI 0.2 to 1.6Denosumab - Placebo
SecondarySerum Type 1 Collagen C-telopeptide (CTX) Percent Change From Baseline at Day 15
Time frame:
From Baseline to Day 15
Reported as:
Median · Percent
Serum Type 1 Collagen C-telopeptide (CTX) Percent Change From Baseline at Day 15
PercentPlaceboDenosumab 60 mg Q6M
Serum Type 1 Collagen C-telopeptide (CTX) Percent Change From Baseline at Day 15-7 (-20 to 16)-81 (-86 to -75)
Statistical analysis
  • Placebo vs Denosumab 60 mg Q6M · Van Elteren Rank Test · p = <0.0001 (p-value is adjusted for multiple comparisons by Hochberg method)Adjusted by level of baseline bone mineral density T-score

Adverse events

Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—10/120 (8.3%)27/120 (22.5%)
Denosumab 60 mg Q6M—11/120 (9.2%)23/120 (19.2%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventPlaceboDenosumab 60 mg Q6M
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1203/120
Arterial thrombosis limbVascular disorders0/1202/120
Acute myocardial infarctionCardiac disorders0/1201/120
Atrial fibrillationCardiac disorders1/1200/120
Myocardial infarctionCardiac disorders0/1201/120
Skull malformationCongenital, familial and genetic disorders1/1200/120
Retinal detachmentEye disorders1/1200/120
Vitreous haemorrhageEye disorders1/1200/120
Pancreatitis acuteGastrointestinal disorders1/1201/120
Chest painGeneral disorders0/1201/120
Most frequent other events
Most frequent other events
EventPlaceboDenosumab 60 mg Q6M
Back painMusculoskeletal and connective tissue disorders8/12010/120
NasopharyngitisInfections and infestations7/1208/120
ArthralgiaMusculoskeletal and connective tissue disorders7/1208/120
ConstipationGastrointestinal disorders7/1200/120

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboDenosumab 60 mg Q6MTotal
Mean65.0 ± 9.164.9 ± 10.565.0 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDenosumab 60 mg Q6MTotal
Female000
Male121121242
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboDenosumab 60 mg Q6MTotal
White or Caucasian107121228
Hispanic or Latino10010
Asian202
Black or African American101
Native Hawaiian or Pacific Islander101
Region of Enrollment
Region of Enrollment(Participants)PlaceboDenosumab 60 mg Q6MTotal
Europe7887165
North America433477
09

Study locations

No study locations are listed for this record.

10

References and documents

Publications

  • Langdahl BL, Teglbjaerg CS, Ho PR, Chapurlat R, Czerwinski E, Kendler DL, Reginster JY, Kivitz A, Lewiecki EM, Miller PD, Bolognese MA, McClung MR, Bone HG, Ljunggren O, Abrahamsen B, Gruntmanis U, Yang YC, Wagman RB, Mirza F, Siddhanti S, Orwoll E. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab. 2015 Apr;100(4):1335-42. doi: 10.1210/jc.2014-4079. Epub 2015 Jan 21. PubMed 25607608 ↗
  • Orwoll E, Teglbjaerg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL, Reginster JY, Kivitz A, Lewiecki EM, Miller PD, Bolognese MA, McClung MR, Bone HG, Ljunggren O, Abrahamsen B, Gruntmanis U, Yang YC, Wagman RB, Siddhanti S, Grauer A, Hall JW, Boonen S. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012 Sep;97(9):3161-9. doi: 10.1210/jc.2012-1569. Epub 2012 Jun 21. PubMed 22723310 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2009 to primary completion in Jun 2011, 20 months.

Results were first posted in Nov 2012, 1 year 5 months after primary completion.

Of 35 industry-sponsored phase 3 interventional studies under Osteoporosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 46. This study's 20 months is below that.

Counting every sponsor, half of 45 studies reached it within 37 months; a quarter within 21 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2009
First posted
Sep 18, 2009
StartActual
Oct 1, 2009
Primary completionActual
Jun 21, 2011
CompletionActual
May 23, 2012
Results first posted
Nov 29, 2012
Last update
Oct 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00980174
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 18, 2009
Start date
Oct 1, 2009
Primary completion
Jun 21, 2011
Completion
May 23, 2012
Results posted
Nov 29, 2012
Last update
Oct 17, 2018

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion